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Abstract
Background: The distribution of HPV genotypes, their association with rigorously confirmed cervical precancer
endpoints, and factors associated with HPV infection have not been previously documented among HIV-infected
women in India. We conducted an observational study to expand this evidence base in this population at high risk of
cervical cancer.
Methods: HIV-infected women (N=278) in Pune, India underwent HPV genotyping by Linear Array assay. Cervical
intraepithelial neoplasia (CIN) disease ascertainment was maximized by detailed assessment using cytology, colposcopy,
and histopathology and a composite endpoint.
Results: CIN2+ was detected in 11.2% while CIN3 was present in 4.7% participants. HPV genotypes were present in 52.5%
(146/278) and ‘carcinogenic’ HPV genotypes were present in 35.3% (98/278) HIV-infected women. ‘Possibly carcinogenic’
and ‘non/unknown carcinogenic’ HPV genotypes were present in 14.7% and 29.5% participants respectively. Multiple ($2)
HPV genotypes were present in half (50.7%) of women with HPV, while multiple ‘carcinogenic’ HPV genotypes were present
in just over a quarter (27.8%) of women with ‘carcinogenic’ HPV. HPV16 was the commonest genotype, present in 12%
overall, as well as in 47% and 50% in CIN2+ and CIN3 lesions with a single carcinogenic HPV infection, respectively. The
carcinogenic HPV genotypes in declining order of prevalence overall included HPV 16, 56, 18, 39, 35, 51, 31, 59, 33, 58, 68, 45
and 52. Factors independently associated with ‘carcinogenic’ HPV type detection were reporting $2 lifetime sexual partners
and having lower CD4+ count. HPV16 detection was associated with lower CD4+ cell counts and currently receiving
combination antiretroviral therapy.
Conclusion: HPV16 was the most common HPV genotype, although a wide diversity and high multiplicity of HPV genotypes
was observed. Type-specific attribution of carcinogenic HPV genotypes in CIN3 lesions in HIV-infected women, and etiologic
significance of concurrently present non/unknown carcinogenic HPV genotypes await larger studies.
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Introduction
Human immunodeficiency virus (HIV)-infected women in India
and other developing countries are living longer in recent years as
a result of improved access to affordable combination antiretro-
viral therapy (cART) drugs. Yet, access to services for prevention
of common HIV-associated malignancies such as invasive cervical
cancer (ICC) caused by carcinogenic human papillomavirus
(HPV) remains inadequate. Thus, HIV-infected women remain
at increased risk for HPV infection and cervical precancerous
lesions (i.e., cervical intraepithelial neoplasia [CIN]) progressing to
ICC. [1,2,3].
Very few studies have described HPV genotype composition
among HIV-infected women in India. [4,5,6] None of these
studies have correlated genotype-specific HPV prevalence against
rigorously verified cervical disease endpoints and immune status of
HIV-infected women. The development of this evidence is critical
to informing the design and delivery of HPV vaccination as well as
HPV-based screening strategies for HIV-infected women.
We conducted an observational study among HIV-infected
women in Pune, India to expand the evidence base of HPV
genotype distribution in this population.
Methods
Ethics Statement
The study protocol was approved by the institutional ethical
review boards of the National AIDS Research Institute, Pune,
India and Vanderbilt University, Nashville, USA. All participants
gave written, informed consent.
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The study was carried out in an outpatient gynecology clinic in
a tertiary care hospital in Pune, India as part of the NIH-ICMR
funded India-US HIV-Cervical Cancer Prevention Research
Consortium. Consecutive women with documented serologic
evidence of HIV infection were enrolled in the study. Participants
were recruited regardless of their CD4+ cell counts or current
status of receiving cART drugs. Exclusion criteria included a
positive urine pregnancy test, debilitating illness that may preclude
a pelvic examination, prior history of screening or treatment for
cervical neoplasia, prior hysterectomy, and presence of current
sexually transmitted infection.
Study Procedures
After explanation of study procedures and written informed
consent,astructuredquestionnairewasadministeredtointerviewthe
participants and collect their sociodemographic information as well
askeybio-behavioralriskfactorsrelevanttoHIV/AIDSandcervical
cancer. Blood samples were obtained for CD4+ T-cell counts
estimation [FACSCount
TM flow cytometry, Becton, Dickinson and
Company,FranklinLakes,NJ,USA].Allenrolledwomenunderwent
a complete physical, pelvic, and colposcopic examination. Trained
nurses collected cervical samples by spatula and cytobrush for
conventional cervical cytology and HPV testing/genotyping. A
standardized non-invasive colposcopy examination was performed
on all participants by trained gynecologists. Confirmatory proce-
duresforhistology[bycervicalpunchbiopsy,endocervicalcurettage
(ECC), and loop electrosurgical excision procedures (LEEP)] were
advised and performedonly onconsenting participantswithclinical
evidence of cervicalabnormalities.
Cervical cytology and histopathology samples were analyzed by
two experienced pathologists who reported diagnosis by consensus.
The pathologists did not have knowledge of the HPV status of the
participant. Cervical cytology results were reported as per revised
(2001) Bethesda classification. [7] Colposcopy and histology results
were reported as per the Richart CIN system. [8] We used results
of both colposcopy/histology and cytology results to define distinct
disease stages of increasing severity of CIN disease in the following
categories: No CIN (normal colposcopy/histology and normal
cytology), CIN1 (CIN1 lesions on colposcopy/histology or cervical
cytology results of either atypical squamous cells of undetermined
significance [ASC-US] or low-grade squamous intraepithelial cells
[LSIL]), CIN2 (CIN2 lesions on colposcopy/histology or high-
grade squamous intraepithelial cells [HSIL] on cervical cytology)
and CIN3 (CIN3 on colposcopy/histology). This classification
ensured that the most severe (abnormal) cellular or tissue detection
of dysplastic changes were included in the appropriate CIN disease
status category.
HPV Genotyping
We performed HPV genotyping on cervical specimens using
PCR-based amplification of target DNA using the Linear ArrayH
HPV genotyping test (LA-HPV) (Roche Molecular Systems,
Pleasanton, CA, USA), an enhanced and commercialized version
of the PGMY line blot assay (PGMY-LB) [9,10,11] The pool of
consensus L1 PGMY09/11 primers used in this assay is designed
to amplify HPV-DNA from 37 genotypes. These include
genotypes characterized by WHO/IARC as ‘carcinogenic’ (13
genotypes): HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68,
‘possibly carcinogenic’ (7 genotypes): HPV26, 53, 66, 67, 70, 73,
82 and ‘non carcinogenic/unknown carcinogenicity’ (17 geno-
types): HPV6, 11, 40, 42, 54, 55, 61, 62, 64, 69, 71, 72, 81, 83, 84,
CP6108, IS39. [12] DNA was extracted from specimen aliquot by
AmpliLute liquid medium extraction kit (Roche Molecular
Diagnostics, Branchburg, NJ, USA). The PCR amplicons were
denatured and subjected to hybridization on LA HPV genotyping
strips coated with HPV type-specific and human b-globin probes
according to manufacturer’s instructions. The biotin-labeled
amplicons hybridized to the probes only if the type-specific
sequence matched those of the amplicons. The biotin-labeled
amplicons were detected by colorimetric development and the
results were read visually by comparing the pattern of colored lines
to the provided reference guide. Each run was performed with
negative and positive controls provided by the manufacturer to
monitor the quality and performance of the assay.
Statistical Analysis
Data were analyzed using STATA intercooled version 10.0 and
IBM SPSS Statistics 19. We analyzed prevalence of individual
HPV genotypes (classified by carcinogenic risk categories and
number of HPV genotypes per woman) in age categories, CD4+
cell strata, and cervical disease stages (No CIN, CIN1, CIN2, and
CIN3). Chi-square test for trend was used to analyze trends in
proportion of women with prevalent HPV genotypes and CIN
status.
We fit bivariate and multivariable logistic regression models to
identify associations between sociodemographic characteristics
(age, marital status, education, family income) and bio-behavioral
factors (parity, age at first sex, number of lifetime sexual partners,
history of STI, tobacco use, CD4+ cell counts, and ART status)
with HPV infection status. The dependent variables included (i)
any prevalent HPV genotype, (ii) any prevalent ‘carcinogenic’
HPV genotypes, (iii) single carcinogenic HPV genotype, (iv)
multiple carcinogenic HPV genotype, (v) HPV16 (the most
common/most carcinogenic genotype), and (vi) any non-HPV16
carcinogenic type. We also evaluated the risk (approximated by
the prevalence odds ratios and their 95% confidence intervals) of
having high-grade cervical precancerous lesions (CIN3 and
CIN2+) with the presence of individual carcinogenic HPV
genotypes (any, single, and multiple), with adjustment (as
appropriate) for age, number of lifetime sexual partners, CD4+
cell counts, and presence of other carcinogenic HPV types. In an
exploratory analysis, this risk of CIN3 and CIN2+ lesions was also
estimated for combinations of individual carcinogenic HPV
genotypes (single and multiple) with the concurrent presence of
single and multiple non-carcinogenic types.
Results
Population Characteristics
A total of 278 HIV-infected women were enrolled for this study.
The mean age was 32.3 years (S.D.: 65.3), a third (89/278, 32%)
were married and cohabiting with their husband, a third (92/278,
33.1%) were illiterate, and a majority (84/278, 57.9%) reported
their family income of ,2500 Indian Rupees per month
(approximately US$55 at the time of the study). Half (137/278,
49.2%) of the participants reported age of first sexual intercourse
as ,18 years, while about one fifth (51/278, 18.3%) reported to
have $2 lifetime sexual partners. Mean and median CD4+ cell
counts were 411 /mL (S.D. 6214) and 372 /mL (interquartile
range: 241–556) respectively.
Cervical Disease Status on Cytology and Colposcopy-
histopathology
Cytology results revealed 7 women with HSIL, 41 with LSIL,
47 with ASC-US, 165 women with no squamous cell abnormality
on cytology, while 18 women had inadequately stained smears.
Colposcopic-histopathologic diagnoses revealed 13 women with
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without any CIN abnormality, while colposcopy was unsatisfac-
tory in 10 women. Three women had both unsatisfactory
colposcopy and also cervical smears that were inadequately
stained, such that the final composite cytologic-colposcopic-
histopathological CIN disease status was able to be determined
for 275 out of 278 women.
The composite cytology-colposcopic-histopathological CIN
diagnosis (N=275) thus included no evidence of CIN in 143/
275 (52%) women, CIN1 (CIN1/ASC-US/LSIL) in 101/275
(36.7%), CIN2 (CIN2/HSIL) in 18/275 (6.5%), and CIN3 in 13/
275 (4.7%) women. Thus, the prevalence of CIN2+ was 11.2%
(31/275) and that of CIN3 was 4.7% (13/275) in this population.
HPV Genotypes by Carcinogenicity Grouping
At least one HPV genotype was detected in 146/278 (52.5%)
participants, while multiple ($2) HPV genotypes were present in
74/146 (50.7%) women. The number of HPV genotypes per
woman ranged between 0–8, with a median of 1 genotype per
woman. ‘Carcinogenic’ HPV genotypes were present in 98/278
(35.3%) women, ‘possibly carcinogenic’ genotypes in 41/278
(14.7%) while ‘non/unknown carcinogenic’ types were detected in
82/278 (29.5%) women. Out of 98 women with presence of any
‘carcinogenic’ HPV genotypes, 71/98 (72.4%) had a single
‘carcinogenic’ HPV genotype, 23/98 (23.4%) had two ‘carcino-
genic’ HPV genotypes, while 4/98 (4.1%) had three ‘carcinogenic’
HPV genotypes, thus a total of 129 individual carcinogenic HPV
infections were identified. Only 17/278 (6.1%) women with
‘possibly carcinogenic’ HPV genotypes and only 35/278 (12.6%)
women with ‘non/unknown carcinogenic’ HPV genotypes were
present without the concurrent presence of ‘carcinogenic’ HPV
genotypes.
The relative proportions of HPV infections (by carcinogenic risk
categories) by age and CD4+ cell count categories are shown in
Figures 1 and 2. The age-specific prevalence revealed a mixed
pattern by carcinogenicity grouping, reflecting a .50% preva-
lence in both the youngest (#25 years of age) as well as the oldest
($41 years) age categories in the study population. (Figure 1)
‘Carcinogenic’ HPV genotypes were higher in prevalence than the
other categories regardless of CD4+ counts, although the
prevalence of HPV in all carcinogenic categories was uniformly
lower than 30% with CD4+ cell counts $400 /mL. (Figure 2).
Relative Prevalence of HPV Genotypes
Of the 37 HPV genotypes identifiable by the Linear Array
assay, all except one (HPV69) were detected in the 278 samples.
The commonest 10 genotypes were HPV16 (12.2%), HPV62
(7.3%), HPV71 (6.5%), HPV53 (6.2%), HPV42 (5.8%), HPV56
and HPV66 (both 4.4%), HPV18 and HPV39 (both 4%), and
HPV35 and HPV51 (both 3.6%). (Table 1) The carcinogenic
HPV types in declining order of prevalence included HPV 16, 56,
18, 39, 35, 51, 31, 59, 33, 58, 68, 45 and 52. (Table 1).
Among the 98 women with a total of 129 ‘carcinogenic’ HPV
infections, HPV16 was the most common (34/129, 26%),
although all 12 other ‘carcinogenic’ HPV genotypes were also
present. (data not shown) Among women with presence of any
single ‘carcinogenic’ HPV infection, as well as in women with
evidence of CIN2+ and CIN3 lesions with single carcinogenic
infections, HPV16 was still the commonest genotype, with an
increasing proportion of 34%, 47%, and 50% respectively. Other
‘carcinogenic’ genotypes-HPV33, HPV39, HPV31, HPV56 and
HPV35 were also present (in respectively decreasing fractions) in
women with CIN2+ and CIN3 lesions with single carcinogenic
HPV genotypes.
At least one HPV genotype was present in 37.1% women with
no CIN lesions, 66.3% in CIN1, 72.2% in CIN2 and 92.3% in
CIN3 (p-for trend ,0.001). (Table 1) The trend for increasing
prevalence of HPV genotypes with increasing severity of cervical
disease was also significant for any ‘carcinogenic’ HPV genotype
(p,0.001), any ‘possibly carcinogenic’ type (p=0.01), any ‘non/
unknown carcinogenic’ HPV genotype (p=0.02), any single or
multiple ‘carcinogenic’ HPV genotype (p,0.001 for both) as well
as for HPV16 (P,0.001), HPV31 (p=0.03), HPV33 (p,0.005)
among ‘carcinogenic’ HPV genotypes. (Table 1).
Risk Factors for HPV Type Positivity
Table 2 shows the results of adjusted (multivariable) models of
factors associated with positivity by any HPV genotype, ‘carcino-
genic’ HPV genotypes (any, single, and multiple) as well as HPV16
and non-HPV16 carcinogenic types. The significant factors
associated with detection of any HPV genotype reporting $2
lifetime sexual partners (Adjusted OR [AOR] 2.72, 95%CI 1.33–
5.56), and having a lower CD4+ counts (AOR=1.21,
95%CI=1.06–1.37, with each 100 units/mL decline). Among
the significant factors associated with any ‘carcinogenic’ HPV
genotype detection were reporting $2 lifetime sexual partners
(AOR 2.41, 95%CI 1.27–4.58) and having a lower CD4+ count
(AOR 1.18, 95%CI 1.03–1.33, with each 100 units/mL decline).
Whereas $2 lifetime number of sexual partners and lower CD4+
count were also significant risk factors for having any multiple
carcinogenic HPV infections, none of these (or any other ) factors
were significantly associated with presence of single carcinogenic
HPV infection. Lower CD4+ cell counts (AOR 1.35, 95%CI 1.09–
1.67) and currently being on cART (AOR 3.47, 95%CI 1.40–
8.59) were both statistically significant factors associated with
presence of HPV16, whereas these were not associated with
presence of non-HPV16 carcinogenic types.
Association of Carcinogenic HPV Genotypes with High
Grade CIN Lesions
When dichotomized at the high grade cervical neoplasia
thresholds (CIN2+ and CIN3) thresholds of the cervical disease
status, women with any HPV infection had higher risk for CIN2+
[Odds Ratio (OR) 4.31(95%CI: 1.71–10.87)] and CIN3 lesions
[OR 11.64 (95%CI:1.49–90.80)] than women without HPV
infection. Similarly, women with any ‘carcinogenic’ HPV geno-
types had higher risk for CIN2+ [OR 5.51 (95%CI: 2.42–12.53]
and CIN3 lesions [OR 6.71(95%CI: 1.80–24.99] than women
without ‘carcinogenic’ HPV infection. Individually, HPV16 was
associated with higher risk of being present in CIN3 (vs. #CIN2)
and CIN2+ (vs. #CIN1) lesions (Odds ratios [OR] 5.2 and 6.7,
respectively), overall, as well as within cases of single carcinogenic
HPV infections (OR: 6.6 and 9.0, respectively) and cases with
presence of multiple carcinogenic infections (OR: 5.3 and 6.5,
respectively). While other carcinogenic HPV genotypes had higher
point estimates of Odds ratios than HPV16, their relative rarity led
to wide 95% confidence intervals. When present as single
carcinogenic HPV infections, HPV16, HPV31 and HPV33 had
statistically significant higher risk of being present in CIN2+ while
HPV16 and HPV33 had higher risk of CIN3. In cases with
multiple carcinogenic infections, HPV16, HPV18, HPV56 and
HPV58 had higher risk of being present in CIN2+ lesions while
HPV58 and HPV68 had higher risk of being present in CIN3
lesions. An exploratory analysis of the risks of various single/
multiple combinations of carcinogenic and non/unknown carci-
nogenic types is presented in Table S1, although the small
numbers precluded the estimation in most models.
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38731Discussion
In this cross sectional study, we have documented the diverse
distribution of HPV genotypes and their associations with
rigorously confirmed cervical precancerous disease endpoints,
and factors associated with HPV infection among HIV-infected
women in India. Overall, the prevalence of any HPV genotypes
was 52.5% and prevalence of any ‘carcinogenic’ HPV genotypes
was 35.3% in this cohort of HIV-infected women. The global
estimates of HPV prevalence among HIV-infected women have
varied by region and the level of the HIV epidemic. [13]
Studies in HIV-infected women from countries with generalized
HIV epidemics, particularly in Africa, have reported a high
(45–90%) carcinogenic HPV prevalence [14,15,16,17] while
studies from concentrated or low-level HIV epidemics in Asia,
including those from India [4,5,18,19], Latin America [20,21],
Europe [22,23], and North America [24,25] have reported
lower (20–40%) carcinogenic HPV prevalence rates among
HIV-infected women. The differences in HPV prevalence in
different geographical locales may be attributed to differing
behavioral and immunological status of the participants, as well
as the differences in primers and sensitivity of the assays used
for PCR.
HPV16 was the commonest genotype (carcinogenic or other-
wise) in our study in this population. It has been hypothesized
HPV16 has better evolutionary ability to escape the effects of
immune surveillance, while non-HPV16 genotypes are often better
controlled by immune response. [26,27] Some studies, especially
in those conducted in severely immunocompromised women and
those not accessing ART [14,27,28] have reported higher relative
preponderance of non-HPV16 genotypes. This is likely reflective
of the loss of immune control against non-HPV16 genotypes in the
context of severe immune suppression, and thus a relative
preponderance along with HPV16. [14,26] Yet, in our study we
did not observe an increase of non-HPV16 carcinogenic genotypes
with worsening immune status; while HPV16 was higher in
women with lower CD4 counts and those currently taking cART.
In fact, other than HPV16, we did not see any differences by ART
status in any carcinogenicity grouping (data not shown). However,
we did not have data on duration of ART to further explore
differences between immune-replete and immunocompetent
women on ART.
The overall diversity of HPV genotypes (regardless of carcino-
genic grouping) found in our study is a characteristic uniformly
reported from HIV-infected populations worldwide. This is in
contrast to the substantially less diversity noted among HIV-
Figure 1. Bar graphs showing HPV genotype prevalence by age categories among HIV-infected women in Pune, India. HPV
prevalence levels (as percentages) are displayed on the Y-axis, with various carcinogenicity groupings (any HPV type, carcinogenic HPV type, possibly
carcinogenic HPV types, and non/unknown carcinogenic types) shown as individual bar graphs grouped by age categories (#25, 26–30, 31–35, 36–
40, & $41 years) on X-axis.
doi:10.1371/journal.pone.0038731.g001
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diversity and multiplicity, particularly those of concurrent ‘non/
unknown carcinogenic’ HPV genotypes, often detected in the
context of HIV-related immunosuppression, is not well under-
stood. [12,29,30,31] That said, our results suggest that future
broad spectrum (polyvalent) HPV vaccines may have better
efficacy in preventing CIN in higher risk groups like HIV-infected
women, than the currently available bivalent (HPV16/18) or
quadrivalent (HPV6/11/16/18) vaccines. [32].
Over half of our participants with HPV infection (74/146,
50.7%) had prevalent detection of multiple ($2) HPV genotypes.
The prevalence of multiple genotypes has varied widely (between
12%–87%) in similar studies worldwide [17,33,34,35,36], and has
been associated with decreased immune response leading to
reactivation of latent HPV genotypes, or reflective of high-risk
sexual behaviors of HIV-infected women or their partners. Both
explanations appear likely in our study, given the increasing
multiplicity of HPV genotypes in women with lower immune
status and higher risk behavior (reflected by number of lifetime
sexual partners). Since multiplicity of HPV infections confounds
exact genotype-specific attribution in cervical lesions, we explored
the risk of cervical high grade neoplastic lesions (CIN3 and
CIN2+) at an individual genotype-specific level, by stratifying as
single or multiple carcinogenic genotypes (Table 3). While often
limited by the small samples size, we have provided a framework
for analysis that can be replicated in larger studies (with more
CIN3/ICC endpoints) to evaluate individual genotype-specific
attributions and elucidate the etiologic role of multiple infections
in cervical carcinogenesis. [37,38,39].
We found that $2 lifetime sexual partners are associated with
presence of any HPV infection, carcinogenic HPV infection,
presence of multiple carcinogenic HPV types, and non-HPV16
carcinogenic types, but not with presence of single carcinogenic
types, and with HPV16. This might be explained by the fact that
HPV16 (which was also the commonest carcinogenic type present
singly) is highly transmittable in comparison with other carcino-
genic types, thus its prevalent detection is regardless of the
multiplicity of sexual partners. It was also noteworthy that other
bio-behavioral factors (e.g., parity, tobacco use) which are
significant HPV co-factors in cervical carcinogenesis were not
significantly associated with HPV infection status. However, we
lacked adequate power to study these associations with HPV
among women with high-grade cervical disease status. Elucidation
of the independent or combined role of such cofactors affecting
risk of carcinogenic HPV and incident cervical precancer and
cancer will only be studied in prospective study designs.
Figure 2. Bar graphs showing HPV genotype prevalence by CD4+ cell count categories among HIV-infected women in Pune, India.
HPV prevalence levels (as percentages) are displayed on the Y-axis, with various carcinogenicity groupings (any HPV type, carcinogenic HPV type,
possibly carcinogenic HPV types, and non/unknown carcinogenic types) shown as individual bar graphs grouped by CD4+ count categories (#199,
200–299, 300–399, 400–499, $500 /mL) on X-axis.
doi:10.1371/journal.pone.0038731.g002
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Overall (N =278) Cervical neoplasia disease status (N=275)
TOTAL No CIN =143 CIN1=101 CIN2=18 CIN3=13
p-value
for trend
N %, (95% CI) %, (95% CI) %, (95% CI) %, (95% CI) %, (95% CI)
Any HPV 146 52.5% (46.6–58.4) 37.1% (31.4–42.8) 66.3% (60.7–71.9) 72.2% (66.9–77.5) 92.3% (89.2–95.5) ,0.001
Carcinogenic HPV 98 35.3% (29.7–40.9) 21.7% (16.8–26.6) 43.6% (37.7–49.5) 66.7% (61.1–72.3) 76.9% (71.9–81.9) ,0.001
Possibly Carc. HPV 41 14.9% (10.7–19.0) 8.4%(5.1–11.7) 23.8% (18.8–28.8) 5.6% (2.9–8.3) 30.8% (25.3–36.3) 0.01
Non/Un. Carc. HPV 82 29.8% (24.4–35.2) 22.4% (17.5–27.3) 36.6% (30.9–42.3) 50% (44.1–55.9) 30.8% (25.3–36.3) 0.02
Single Carc. HPV 70 25.5% (20.4–30.6) 18.8% (14.2–23.4) 33.7% (28.1–39.3) 53.9% (48–59.8) 72.7% (67.4–77.9) ,0.001
Multiple Carc. HPV 27 9.8% (6.3–13.3) 4.3% (1.9–6.7) 20.8% (16–25.6) 45.5% (39.2–51.4) 40.0% (34.2–45.8) ,0.001
Carcinogenic HPV genotypes
HPV 16 34 12.2% (8.4–16.0) 5.6% (2.9–8.3) 14.9% (10.7–19.1) 27.8% (22.5–33.1) 38.5% (32.6–44.3) ,0.001
HPV 18 11 4.0% (1.7–6.3) 2.1% (0.4–3.8) 5.0% (2.4–7.6) 11.1% (7.4–14.8) 7.7% (4.6–10.9) 0.06
HPV 31 9 3.2% (1.1–5.3) 0.7% (0–1.7) 5.9% (3.1–8.7) 5.6% (2.9–8.3) 7.7% (4.6–10.9) 0.03
HPV 33 7 2.5% (0.7–4.3) 0.7% (0–1.7) 3.0% (0.9–5.0) 5.6% (2.9–8.3) 15.4% (11.1–19.7) ,0.005
HPV 35 10 3.6% (1.4–5.8) 2.8% (0.9–4.8) 4.0% (1.7–6.3) 11.1% (7.4–14.8) 0% 0.52
HPV 39 11 4.0% (1.7–6.3) 2.8% (0.9–4.8) 5.0% (2.4–7.6) 5.6% (2.9–8.3) 7.7% (4.6–10.9) 0.26
HPV 45 3 1.1% (0–2.3) 0% 2.0% (0.4–3.7) 5.6% (2.9–8.3) 0% 0.13
HPV 51 10 3.6% (1.4–5.8) 2.1% (0.4–3.8) 5.0% (2.4–7.6) 11.1% (7.4–14.8) 0% 0.30
HPV 52 3 1.1% (–0.1–2.3) 1.4% (0.01–2.8) 1.0% (–0.2–2.9) 0% 0% 0.51
HPV 56 12 4.3% (1.9–6.7) 2.8% (0.9–4.8) 5.0% (2.4–7.6) 16.7% (12.3–21.1) 0% 0.22
HPV 58 6 2.2% (0.5–3.9) 1.4% (0.01–2.8) 2.0% (0.4–3.7) 5.6% (2.9–8.3) 7.7% (4.6–10.9) 0.11
HPV 59 8 2.9% (0.9–4.9) 2.8% (0.9–4.8) 3.0% (0.9–5.0) 5.6% (2.9–8.3) 0% 0.96
HPV 68 5 1.8% (0.2–3.4) 0.7% (0–1.7) 3.0% (0.9–5.0) 0% 7.7% (4.6–10.9) 0.12
‘Possibly’ carcinogenic HPV genotypes
HPV 26 2 0.7% (0–1.7) 1.4% (0.01–2.8) 0% 0% 0% 0.26
HPV 53 17 6.1% (3.3–8.9) 3.5% (1.3–5.7) 9.9% (6.4–13.4) 0% 15.4% (11.1–19.7) 0.11
HPV 66 12 4.3% (1.9–6.7) 1.4% (0.01–2.8) 8.9% (5.5–12.3) 5.6% (2.9–8.3) 0% 0.22
HPV 67 2 0.7% (0–1.7) 0% 1.0% (0–2.2) 0% 7.7% (4.6–10.9) 0.02
HPV 70 6 2.2% (0.5–3.9) 2.1% (0.4–3.8) 3.0% (0.9–5.0) 0% 0% 0.67
HPV 73 5 1.8% (0.2–3.4) 0% 4.0% (1.7–6.3) 0% 7.7% (4.6–10.9) 0.03
HPV 82 2 0.7% (0–1.7) 0.7% (0–1.7) 1.0% (0–2.2) 0% 0% 0.81
Individual ‘Non-carcinogenic’ or ‘Unknown carcinogenic’ HPV genotype
HPV 6 2 0.7% (0–1.7) 0.7% (0–1.7) 0% 5.6% (2.9–8.3) 0% 0.53
HPV 11 1 0.4% (0–1.1) 0% 1.0% (0–2.2) 0% 0% 0.65
HPV 40 3 1.1% (0–2.3) 0.7% (0–1.7) 2.0% (0.4–3.7) 0% 0% 0.95
HPV 42 16 5.8% (3.0–8.6) 4.9% (2.4–7.5) 6.9% (3.9–9.9) 5.6% (2.9–8.3) 7.7% (4.6–10.9) 0.57
HPV 54 6 2.2% (0.5–3.9) 1.4% (0.01–2.8) 3.0% (0.9–5.0) 5.6% (2.9–8.3) 0% 0.55
HPV 55 1 0.4% (0–1.1) 0% 1% (0–2.2) 0% 0% 0.65
HPV 61 9 3.2% (1.1–5.3) 2.8% (0.9–4.8) 5.0% (2.4–7.6) 0% 0% 0.75
HPV 62 20 7.2% (4.2–10.2) 5.6% (2.9–8.3) 8.9% (5.5–12.3) 11.1% (7.4–14.8) 7.7% (4.6–10.9) 0.36
HPV 64 2 0.7% (0–1.7) 0% 2.0% (0.4–3.7) 0% 0% 0.53
HPV 69 0 – – – – – –
HPV 71 18 6.5% (3.6–9.4) 6.3% (3.4–9.2) 6.9% (3.9–9.9) 11.1% (7.4–14.8) 0% 0.88
HPV 72 13 4.7% (2.2–7.2) 2.1% (0.4–3.8) 5.9% (3.1–8.7) 16.7% (12.3–21.1) 7.7% (4.6–10.9) 0.02
HPV 81 6 2.2% (0.5–3.9) 0% 4.0% (1.7–6.3) 5.6% (2.9–8.3) 7.7% (4.6–10.9) 0.01
HPV 83 3 1.1% (0–2.3) 1.4% (0.01–2.8) 1.0% (0–2.2) 0% 0% 0.51
HPV 84 8 2.9% (0.9–4.9) 2.1% (0.4–3.8) 5.0% (2.4–7.6) 0% 0% 0.96
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38731Table 2. Association between participants’ characteristics and presence of HPV (any HPV types, carcinogenic HPV types, single
carcinogenic HPV type, multiple carcinogenic HPV types, HPV16, and non-HPV16 carcinogenic types) in HIV-infected women in
Pune, India: results of multivariable logistic regression analyses.
N Any HPV type
Any
Carcinogenic
HPV type
Any Single
Carcinogenic
HPV type
Multiple
Carcinogenic
HPV types HPV16
Non-HPV16
Carcinogenic HPV
types
AOR [95%CI] AOR [95%CI] AOR [95%CI] AOR [95%CI] AOR [95%CI] AOR [95%CI]
Age (per year increase) 278 1.04 [0.98–1.09] 1.01 [0.96–1.07] 1.04 [0.98–1.10] 0.92 [0.82–1.03] 0.98 [0.90–1.06] 1.03 [0.96–1.09]
Marital Status
Married, cohabiting 89 0.7 [0.38–1.30] 0.88 [0.47–1.63] 0.66 [0.33–1.34] 2.02 [0.68–6.02] 0.88 [0.36–2.15] 0.89 [0.43–1.83]
Non-cohabiting/others 189 1 1 1111
Education
Primary school or less 92 1.44 [0.76–2.73] 1.25 [0.65–2.40] 1.11 [0.53–2.31] 1.62 [0.50–5.25] 2.05 [0.80–5.25] 1.0 [0.45–2.24]
High school and above 186 1 1 1111
Family income (Rs)
,2500 per month 161 0.60 [0.33–1.09] 0.76 [0.42–1.38] 0.84 [0.43–1.64] 0.47 [0.16–1.40] 0.62 [0.26–1.47] 0.85 [0.43–1.71]
.=2500 per month 116 1 1 1111
Parity
4 or more 76 1.35 [0.74–2.49] 1.11 [0.60–2.05] 1.16 [0.59–2.29] 0.73 [0.23–2.34] 1.26 [0.51–3.10] 1.0 [0.49–2.06]
3 or less 202 1 1 1111
Age at first sex
,=18 years 137 1.66 [0.94–2.96] 1.16 [0.65–2.09] 1.30 [0.68–2.48] 0.80 [0.28–2.33] 1.08 [0.46–2.54] 1.13 [0.57–2.26]
.18 years 141 1 1 1111
Lifetime sex partners
2 or more 49 2.72 [1.33–5.56] 2.25 [1.16–4.37] 1.79 [0.86–3.73] 3.95 [1.28–12.26] 1.07 [0.39–2.97] 2.58 [1.24–5.39]
O n e 2 2 7 1 1 1111
Past history of STI
Yes 89 0.83 [0.46–1.47] 0.93 [0.51–1.68] 0.88 [0.46–1.69] 1.16 [0.38–3.55] 1.12 [0.47–2.66] 0.86 [0.43–1.72]
N o 1 8 8 1 1 1111
Tobacco use
Yes 76 1.28 [0.70–2.36] 1.26 [0.69–2.29] 1.32 [0.69–2.54] 0.89 [0.29–2.69] 1.04 [0.43–2.51] 1.31 [0.66–2.61]
N o 2 0 2 1 1 1111
CD4+ (decline by 100) 269 1.21 [1.06–1.37] 1.18 [1.04–1.35] 1.09 [0.99–1.25] 1.59 [1.19–2.13] 1.35 [1.09–1.67] 1.09 [0.94–1.26]
Currently on ART
Yes 154 1.41 [0.82–2.43] 1.46 [0.84–2.55] 1.49 [0.80–2.76] 1.23 [0.44–3.41] 3.47 [1.40–8.59] 0.96 [0.51–1.81]
N o 1 2 3 1 1 1111
Footnotes to Table 2: Abbreviations: HPV: human papillomavirus, STI: sexually transmitted infection, ART: antiretroviral therapy,
AOR: adjusted odds ratio, 95%CI: Lower limits and upper limits of the 95% Confidence intervals. All Odds ratios presented in this table are adjusted (through
multivariable logistic regression) for the covariates presented.
doi:10.1371/journal.pone.0038731.t002
Table 1. Cont.
Overall (N =278) Cervical neoplasia disease status (N=275)
TOTAL No CIN =143 CIN1=101 CIN2=18 CIN3=13
p-value
for trend
N %, (95% CI) %, (95% CI) %, (95% CI) %, (95% CI) %, (95% CI)
HPV CP6108 5 1.8% (0.2–3.4) 1.4% (0.01–2.8) 2.0% (0.4–3.7) 5.6% (2.9–8.3) 0% 0.65
HPV IS39 1 0.4% (0–1.1) 0% 1% (0–2.2) 0% 0% 0.65
Footnotes to Table 1: Abbreviations: ‘Carc’: Carcinogenic, ‘Non/Un.’: Non/unknown, CIN: cervical intraepithelial neoplasia, HPV: human papillomavirus, 95%CI: Lower
limits and upper limits of the 95% Confidence intervals.
*CIN1= CIN1 on Colposcopy/histopathology & ASC-US/LSIL on cytology, CIN2= CIN2 on colposcopy/histopathology & HSIL on cytology; 3 women did not undergo
colposcopy or cytology, hence the sum of numbers of women with confirmed cervical disease status is n=275, not n=278.
doi:10.1371/journal.pone.0038731.t001
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genotypes, the LA-HPV assay also has certain limitations like
cross-hybridization of the HPV52 probe with that of HPV33,
HPV35, and HPV58 (although we only analyzed HPV52 without
concurrent present of these other genotypes), lack of quantitation
of HPV viral load, and chances of carry-over contamination. [40]
Yet, it remains the most widely used and comprehensive
commercially available assay for detection of a wide range of
HPV genotypes simultaneously.
India has a high case burden of HIV/AIDS (estimated 2.4
million persons, including 1 million women) as well as a high
incidence of ICC (estimated 130,000 new cases and 74,000 deaths
annually). [41,42] HIV-infected women in India are now living
longer due to improved access to affordable cART in recent years.
In absence of effective cervical cancer prevention services, HIV-
infected women are at increased risk of ICC. Our findings add to
the national and global data of HPV genotypes among HIV-
infected populations. This evidence could inform the projected
effectiveness of prophylactic vaccination strategies, provide back-
ground data for cost effectiveness and decision analysis models,
and inform the design of HPV-based genotyping assays and
biomarkers as improved screening strategies. [43] The high
prevalence of carcinogenic HPV reinforces the importance of
regular and vigilant screening for cervical cancer and anogenital
tract pathologies in this population, especially among those with
lower CD4+ counts. The results also emphasize the need for larger
and prospective cohort studies to further elucidate the association
between immunosuppression and HPV risk, and the etiologic
significance of multiple HPV infections among HIV-infected
women.
Supporting Information
Table S1 Relationship of prevalent carcinogenic and concurrent
non/unknown-carcinogenic types (single or multiple) with risk of
CIN2+ and CIN3 in HIV-infected women.
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Table 3. Relationship of prevalent carcinogenic HPV genotypes (present singly or concurrently with carcinogenic types) with risk
of CIN2+ and CIN3 in HIV-infected women in Pune, India.
Risk of CIN2+(vs. ,CIN1) Risk of CIN3 (vs. ,CIN2)
Presence of any
HPV type
Presence of
single
carcinogenic
HPV type
Presence of
multiple (.2)
carcinogenic HPV
types
Presence of any
HPV type
Presence of single
carcinogenic HPV
type
Presence of multiple
(.2) carcinogenic
HPV types
OR (95%CI)
1 OR (95%CI)
1 OR (95%CI)
2 OR (95%CI)
3 OR (95%CI)
3 OR (95%CI)
3
HPV16 6.7 (2.4, 18.8) 9.0 (2.8,28.7) 6.5 (1.2, 37.2) 5.2(1.6, 17.1) 6.6 (1.8, 24.4) 5.3 (0.5, 52.4)
HPV18 7.6 (1.1, 51.0) – 8.9 (1.6, 48.9) 2.1 (0.2, 17.8) – 6.9 (0.7, 69.9)
HPV31 6.7 (1.1, 40.3) 8.2 (1.3, 52.8) – 2.6 (0.3, 22.9) 3.9 (0.4, 35.1) –
HPV33 26.0 (3.4, 198.9) 23.0 (2.6, 202.0) – 9.3 (1.6,53.6) 26 (3.3, 206.9) –
HPV35 0.9 (0.1, 6.8) 6.6 (0.6, 76.3) 2.2 (0.2, 21.9) – – –
HPV39 1.8 (0.2 19.0) 3.6 (0.4, 34.6) – 2.1 (0.2, 17.8) 2.9 (0.3, 25.2) –
HPV45 7.8 (0.4, 148.8) – 9.4 (0.5, 173.9) – – –
HPV51 0.3 (0.0, 3.9) – 6.9(0.7, 68.1) – – –
HPV52 – – – – – –
HPV56 2.8 (0.6, 14.6) 3.4 (0.4, 32.9) 7.9 (1.2, 55.1) – – –
HPV58 7.3 (0.8, 66.1) – 12.4 (1.5, 99.6) 4.3 (0.5, 39.6) – 12.3 (1.1, 135.6)
HPV59 0.4 (0, 7.6) – 2.8 (0.3, 31.0) – – –
HPV68 1.6 (0.1, 21.3) – 3.2 (0.3, 34.0) 5.4 (0.6, 51.8) – 16.4 (1.4, 194.1)
Footnotes to Table 3: Abbreviations: OR: Odds ratios, 95%CI: Lower limits and upper limits of the 95% Confidence intervals, CIN: Cervical intraepithelial neoplasia, HPV:
human papillomavirus.
1Odds ratios adjusted for age, number of lifetime sexual partners, CD4+ cell counts, and presence of other carcinogenic HPV types.
2Odds ratios adjusted for age, number of lifetime sexual partners, and CD4+ cell counts.
3Odds ratios not adjusted for any factors due to small sample size.
doi:10.1371/journal.pone.0038731.t003
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